{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2009"],"condition":["Metastatic Colorectal Cancer","Colorectal Neoplasms"],"disease":["Metastatic Colorectal Cancer","Colorectal Neoplasms"],"study_type":["Observational"],"full_dataset_link":["https://newmdr.ecrin.org/Study/2103436"],"location":["Saudi Arabia"],"study_start_month":["1"],"keyword":["Irinotecan","Oxaliplatin","Capecitabine","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Not provided"],"additional_accession":[]},"is_claimable":false,"name":"A Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination With Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer","description":"A Phase I-II Trial of Capecitabine (Xeloda), Oxaliplatin and Irinotecan in Combination with Bevacizumab in 1st Line Treatment of Metastatic Colorectal Cancer","dates":{"creation":"2009-01-15"},"accession":"2103436","cross_references":{"ClinicalTrials___gov":["NCT01311050"]}}